Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients

González-Sánchez, Marta|||0000-0001-9155-1438; Jiménez, Javier; Narváez García, Arantzazu|||0000-0001-8141-558X; Antequera, Desiree; Llamas-Velasco, Sara|||0000-0002-9174-2610; Herrero San-Martín, Alejandro; Molina Arjona, Jose Antonio; Lopez de Munain, Adolfo|||0000-0002-9509-4032; Lleó, Alberto|||0000-0002-2568-5478; Marco, María Pilar|||0000-0002-4064-1668; Rodríguez-Núñez, Montserrat; Pérez-Martínez, David Andrés|||0000-0001-5587-0415; Villarejo-Galende, Alberto|||0000-0002-6834-7620; Bartolome, Fernando|||0000-0001-9322-8933; Domínguez, Elena; Carro, Eva M.

Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients

Kynurenic acid (KYNA) is a product of the tryptophan (TRP) metabolism via the kynurenine pathway (KP). This pathway is activated in neurodegenerative disorders, such as Alzheimer's disease (AD). KYNA is primarily produced by astrocytes and is considered neuroprotective. Thus, altered KYNA level...

Descripción completa

Detalles Bibliográficos
Autores:	González-Sánchez, Marta\|\|\|0000-0001-9155-1438, Jiménez, Javier, Narváez García, Arantzazu\|\|\|0000-0001-8141-558X, Antequera, Desiree, Llamas-Velasco, Sara\|\|\|0000-0002-9174-2610, Herrero San-Martín, Alejandro, Molina Arjona, Jose Antonio, Lopez de Munain, Adolfo\|\|\|0000-0002-9509-4032, Lleó, Alberto\|\|\|0000-0002-2568-5478, Marco, María Pilar\|\|\|0000-0002-4064-1668, Rodríguez-Núñez, Montserrat, Pérez-Martínez, David Andrés\|\|\|0000-0001-5587-0415, Villarejo-Galende, Alberto\|\|\|0000-0002-6834-7620, Bartolome, Fernando\|\|\|0000-0001-9322-8933, Domínguez, Elena, Carro, Eva M.
Tipo de recurso:	artículo
Fecha de publicación:	2020
País:	España
Institución:	Universitat Autònoma de Barcelona
Repositorio:	Dipòsit Digital de Documents de la UAB
Idioma:	inglés
OAI Identifier:	oai:ddd.uab.cat:283713
Acceso en línea:	https://ddd.uab.cat/record/283713 https://dx.doi.org/urn:doi:10.3390/biom10040571
Access Level:	acceso abierto
Palabra clave:	Alzheimer's disease Amyloid-β Biomarkers Cerebrospinal fluid Kynurenine pathway Tau protein

id	ES_8c97fbcfb8d84ed1017cae100db06a5e
oai_identifier_str	oai:ddd.uab.cat:283713
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Kynurenic acid levels are increased in the CSF of Alzheimer's disease patientsGonzález-Sánchez, Marta\|\|\|0000-0001-9155-1438Jiménez, JavierNarváez García, Arantzazu\|\|\|0000-0001-8141-558XAntequera, DesireeLlamas-Velasco, Sara\|\|\|0000-0002-9174-2610Herrero San-Martín, AlejandroMolina Arjona, Jose AntonioLopez de Munain, Adolfo\|\|\|0000-0002-9509-4032Lleó, Alberto\|\|\|0000-0002-2568-5478Marco, María Pilar\|\|\|0000-0002-4064-1668Rodríguez-Núñez, MontserratPérez-Martínez, David Andrés\|\|\|0000-0001-5587-0415Villarejo-Galende, Alberto\|\|\|0000-0002-6834-7620Bartolome, Fernando\|\|\|0000-0001-9322-8933Domínguez, ElenaCarro, Eva M.Alzheimer's diseaseAmyloid-βBiomarkersCerebrospinal fluidKynurenine pathwayTau proteinKynurenic acid (KYNA) is a product of the tryptophan (TRP) metabolism via the kynurenine pathway (KP). This pathway is activated in neurodegenerative disorders, such as Alzheimer's disease (AD). KYNA is primarily produced by astrocytes and is considered neuroprotective. Thus, altered KYNA levels may suggest an inflammatory response. Very recently, significant increases in KYNA levels were reported in cerebrospinal fluid (CSF) from AD patients compared with normal controls. In this study, we assessed the accuracy of KYNA in CSF for the classification of patients with AD, cognitively healthy controls, and patients with a variety of other neurodegenerative diseases, including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and progressive supranuclear palsy (PSP). Averaged KYNA concentration in CSF was higher in patients with AD when compared with healthy subjects and with all the other differentially diagnosed groups. There were no significant differences in KYNA levels in CSF between any other neurodegenerative groups and controls. These results suggest a specific increase in KYNA concentration in CSF from AD patients not seen in other neurodegenerative diseases.Universitat Autònoma de Barcelona 22020-01-0120202020-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/283713https://dx.doi.org/urn:doi:10.3390/biom10040571reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengInstituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18/00118Ministerio de Ciencia e Innovación https://doi.org/10.13039/501100004837 CTQ2011-29163-C03-01open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2837132026-06-06T12:50:31Z
dc.title.none.fl_str_mv	Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients
title	Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients
spellingShingle	Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients González-Sánchez, Marta\|\|\|0000-0001-9155-1438 Alzheimer's disease Amyloid-β Biomarkers Cerebrospinal fluid Kynurenine pathway Tau protein
title_short	Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients
title_full	Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients
title_fullStr	Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients
title_full_unstemmed	Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients
title_sort	Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients
dc.creator.none.fl_str_mv	González-Sánchez, Marta\|\|\|0000-0001-9155-1438 Jiménez, Javier Narváez García, Arantzazu\|\|\|0000-0001-8141-558X Antequera, Desiree Llamas-Velasco, Sara\|\|\|0000-0002-9174-2610 Herrero San-Martín, Alejandro Molina Arjona, Jose Antonio Lopez de Munain, Adolfo\|\|\|0000-0002-9509-4032 Lleó, Alberto\|\|\|0000-0002-2568-5478 Marco, María Pilar\|\|\|0000-0002-4064-1668 Rodríguez-Núñez, Montserrat Pérez-Martínez, David Andrés\|\|\|0000-0001-5587-0415 Villarejo-Galende, Alberto\|\|\|0000-0002-6834-7620 Bartolome, Fernando\|\|\|0000-0001-9322-8933 Domínguez, Elena Carro, Eva M.
author	González-Sánchez, Marta\|\|\|0000-0001-9155-1438
author_facet	González-Sánchez, Marta\|\|\|0000-0001-9155-1438 Jiménez, Javier Narváez García, Arantzazu\|\|\|0000-0001-8141-558X Antequera, Desiree Llamas-Velasco, Sara\|\|\|0000-0002-9174-2610 Herrero San-Martín, Alejandro Molina Arjona, Jose Antonio Lopez de Munain, Adolfo\|\|\|0000-0002-9509-4032 Lleó, Alberto\|\|\|0000-0002-2568-5478 Marco, María Pilar\|\|\|0000-0002-4064-1668 Rodríguez-Núñez, Montserrat Pérez-Martínez, David Andrés\|\|\|0000-0001-5587-0415 Villarejo-Galende, Alberto\|\|\|0000-0002-6834-7620 Bartolome, Fernando\|\|\|0000-0001-9322-8933 Domínguez, Elena Carro, Eva M.
author_role	author
author2	Jiménez, Javier Narváez García, Arantzazu\|\|\|0000-0001-8141-558X Antequera, Desiree Llamas-Velasco, Sara\|\|\|0000-0002-9174-2610 Herrero San-Martín, Alejandro Molina Arjona, Jose Antonio Lopez de Munain, Adolfo\|\|\|0000-0002-9509-4032 Lleó, Alberto\|\|\|0000-0002-2568-5478 Marco, María Pilar\|\|\|0000-0002-4064-1668 Rodríguez-Núñez, Montserrat Pérez-Martínez, David Andrés\|\|\|0000-0001-5587-0415 Villarejo-Galende, Alberto\|\|\|0000-0002-6834-7620 Bartolome, Fernando\|\|\|0000-0001-9322-8933 Domínguez, Elena Carro, Eva M.
author2_role	author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv	Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv	Alzheimer's disease Amyloid-β Biomarkers Cerebrospinal fluid Kynurenine pathway Tau protein
topic	Alzheimer's disease Amyloid-β Biomarkers Cerebrospinal fluid Kynurenine pathway Tau protein
description	Kynurenic acid (KYNA) is a product of the tryptophan (TRP) metabolism via the kynurenine pathway (KP). This pathway is activated in neurodegenerative disorders, such as Alzheimer's disease (AD). KYNA is primarily produced by astrocytes and is considered neuroprotective. Thus, altered KYNA levels may suggest an inflammatory response. Very recently, significant increases in KYNA levels were reported in cerebrospinal fluid (CSF) from AD patients compared with normal controls. In this study, we assessed the accuracy of KYNA in CSF for the classification of patients with AD, cognitively healthy controls, and patients with a variety of other neurodegenerative diseases, including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and progressive supranuclear palsy (PSP). Averaged KYNA concentration in CSF was higher in patients with AD when compared with healthy subjects and with all the other differentially diagnosed groups. There were no significant differences in KYNA levels in CSF between any other neurodegenerative groups and controls. These results suggest a specific increase in KYNA concentration in CSF from AD patients not seen in other neurodegenerative diseases.
publishDate	2020
dc.date.none.fl_str_mv	2 2020-01-01 2020 2020-01-01
dc.type.none.fl_str_mv	Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://ddd.uab.cat/record/283713 https://dx.doi.org/urn:doi:10.3390/biom10040571
url	https://ddd.uab.cat/record/283713 https://dx.doi.org/urn:doi:10.3390/biom10040571
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.relation.none.fl_str_mv	Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18/00118 Ministerio de Ciencia e Innovación https://doi.org/10.13039/501100004837 CTQ2011-29163-C03-01
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.source.none.fl_str_mv	reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona
instname_str	Universitat Autònoma de Barcelona
reponame_str	Dipòsit Digital de Documents de la UAB
collection	Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869412945691148289
score	15.300719

Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients

Similares en LA Referencia